• Sorafenib (BAY-43-9006): Advanced Cancer Biology Research To

  2026-04-22

  Sorafenib, a multikinase inhibitor targeting Raf and VEGFR, empowers oncology researchers to dissect proliferation and angiogenesis in both cell-based and in vivo models. This guide translates the latest mechanistic findings and hands-on protocols into actionable strategies for maximizing experimental success with Sorafenib from APExBIO.

• Patient-Derived Gastric Cancer Assembloids: Advancing Tumor-

  2026-04-21

  This study presents a robust patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, more accurately recapitulating tumor microenvironment complexity. The model reveals critical influences of stromal cells on drug response, providing an improved platform for personalized therapy development and drug screening.

• Applied Uses of 12-O-tetradecanoyl phorbol-13-acetate (TPA)

  2026-04-21

  12-O-tetradecanoyl phorbol-13-acetate (TPA) is a gold-standard ERK/MAPK pathway activator, enabling reproducible workflows in kinase assays, skin cancer modeling, and immune modulation studies. This guide details step-by-step protocols, advanced applications, troubleshooting, and new insights from immune research to maximize the impact of TPA in translational settings.

• Pexmetinib (ARRY-614): Optimizing Dual Inhibition in Cytokin

  2026-04-20

  Pexmetinib (ARRY-614) enables precise, dual pathway modulation in inflammation and myelodysplastic syndrome research, offering robust cytokine inhibition and fine-tuned experimental control. This guide spotlights validated workflows, troubleshooting strategies, and actionable insights, translating bench innovation into reproducible results.

• CCG-1423: Precision RhoA Inhibitor for Cancer Research & Vir

  2026-04-20

  CCG-1423 uniquely disrupts the RhoA transcriptional pathway, enabling high-fidelity studies of cancer cell invasion, apoptosis, and viral entry mechanisms. This guide translates cutting-edge findings and troubleshooting strategies into actionable workflows for researchers leveraging APExBIO’s trusted RhoA inhibitor.

• Bradford Protein Assay Kit: Reliable Protein Quantification

  2026-04-19

  The Bradford Protein Assay Kit (SKU: K4103) enables rapid, sensitive, and reproducible quantification of protein concentrations in solution, making it suitable for workflows that demand quick turnaround with minimal sample input. It is not recommended for samples with interfering detergents or protocols requiring a broad dynamic range, as per the product specification.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1 in NF-κB

  2026-04-18

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1 from APExBIO, unlocks advanced workflows for dissecting the ubiquitin-proteasome system and modulating NF-κB signaling. Its broad utility in apoptosis assays, inflammation models, and protein stability studies delivers quantifiable and reproducible results for translational research.

• Cy3-UTP: Advanced Fluorescent RNA Labeling for Dynamic Studi

  2026-04-17

  Cy3-UTP enables precise, photostable fluorescent labeling of RNA for real-time imaging, RNA-protein interaction studies, and detection assays. Its integration into in vitro transcription workflows unlocks single-nucleotide resolution of RNA conformational dynamics and quantitative cellular tracking, backed by robust experimental protocols and troubleshooting strategies.

• Chloroquine Diphosphate: Mechanisms and Evidence in Autophag

  2026-04-16

  Chloroquine diphosphate is a well-characterized modulator of autophagy and an inhibitor of TLR7/9, with robust evidence for its use in cancer research and cell cycle modulation. Its mechanism involves p53/p27 upregulation and CDK2/cyclin D1 downregulation, arresting cells in G1. APExBIO offers a research-grade product (SKU A8628) with detailed solubility and storage guidance for reproducible results.

• 17-AAG (Tanespimycin): Catalyzing Next-Gen Translational Onc

  2026-04-15

  This thought-leadership article explores the mechanistic and translational advances enabled by 17-AAG (Tanespimycin), a potent HSP90 inhibitor, in cancer research. We integrate emerging insights on programmed cell death, NINJ1-mediated DAMP release, and strategic guidance for translational researchers. By contextualizing 17-AAG’s unique value in destabilizing oncogenic clients and influencing regulated cell death, we illuminate new frontiers for oncology innovation and highlight APExBIO’s role in enabling discovery.

• BIRB 796 (Doramapimod): Precision p38α MAPK Inhibition Workf

  2026-04-14

  BIRB 796 (Doramapimod) empowers advanced inflammation and apoptosis research with unmatched selectivity and allosteric potency. Learn how to maximize experimental reproducibility and data clarity using validated workflows, troubleshooting strategies, and insights from the latest dual-action kinase inhibitor studies.

• Ribociclib Succinate (LEE011): Advanced Insights into CDK In

  2026-04-13

  Explore the unique pH-independent pharmacology of Ribociclib succinate (LEE011 succinate), a leading CDK inhibitor, and discover how recent analytical advances inform cancer research protocols and assay design.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-04-13

  This study demonstrates that pharmacological inhibition of SMYD2, using agents such as LLY-507, significantly reduces renal fibrosis and inflammation in a cisplatin-induced chronic kidney disease model. The findings highlight SMYD2 as a promising therapeutic target in renal fibrosis and provide mechanistic insight into the role of epigenetic regulation in kidney pathology.

• RWJ 67657: Structural Insights Redefining p38α/β Inhibition

  2026-04-12

  Discover how RWJ 67657 (JNJ-3026582) leverages novel structural mechanisms to advance p38 MAP kinase inhibition and inflammatory disease research. This article uniquely explores conformational control and practical assay implications, setting it apart within the field.

• Norovirus Hijacks NINJ1 to Enable Selective Viral Protein Se

  2026-04-12

  Song et al. reveal that murine norovirus exploits the cell death effector NINJ1 to selectively secrete its viral NS1 protein, a process dependent on caspase-3 activity and distinct from general DAMP release. This study advances understanding of viral manipulation of host cell death pathways and uncovers new mechanistic details relevant to both virology and cell biology.

16207 records 1/1081 page Next 12345 下5页 Last page